Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma

Digestive Diseases and Sciences

Volumn 58, Issue 7, 2013, Pages 1916-1922

  Hyeon, Jiyeon ^a   Ahn, Soomin ^a   Lee, Jae Jun ^a   Song, Dae Hyun ^a   Park, Cheol Keun ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

FGF19; Hepatocellular carcinoma; Recurrence; Survival

Indexed keywords

ALBUMIN; FIBROBLAST GROWTH FACTOR 19;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; VIRUS ETIOLOGY;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84879845933     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2609-x     Document Type: Article

References (24)

1. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181-200.
2. Poon RT. Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge. Hepatology. 2011;54:757-759.
3. Ho MC, Lin JJ, Chen CN, et al. A gene expression profile for vascular invasion can predict the recurrence after resection of hepatocellular carcinoma: a microarray approach. Ann Surg Oncol. 2006;13:1474-1484.
4. Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol. 2004;130:497-513.
5. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001;2:reviews3005.1-12.
6. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer. 2000;7:165-197.
7. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 2007;282:26687-26695.
8. Pai R, Dunlap D, Qing J, et al. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating β-catenin signaling. Cancer Res. 2008;68:5086-5095.
9. French DM, Lin BC, Wang M, et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One. 2012;7:e36713.
10. Nicholes K, Guillet S, Tomlinson E, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol. 2002;160:2295-2307.
11. Desnoyers LR, Pai R. Ferrando RE, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene. 2008;27:85-97.
12. Sawey ET, Chanrion M, Cai C, et al. Identification of therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell. 2011;19:347-358.
13. Miura S, Mitsuhashi N, Shimizu H, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer. 2012;12:56.
14. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503.
15. Kumada T, Nakano S, Takeda I, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology. 1997;25:87-92.
16. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A III. AJCC cancer staging manual. 7th ed. Chicago, IL: Springer; 2010.
17. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-338.
18. Shimada M, Hamatsu T, Yamashita Y, et al. Characteristics of multicentric hepatocellular carcinomas: comparison with intrahepatic metastasis. World J Surg. 2001;25:991-995.
19. Imamura H, Matsuyama Y, Tanaka T, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200-207.
20. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359:1995-2004.
21. Kim SH, Ahn S, Park CK. Smad3 and its phosphoisoforms are prognostic predictors of hepatocellular carcinoma after curative hepatectomy. Hepatobiliary Pancreat Dis Int. 2012;11:51-59.
22. Katzmann DJ, Odorizzi G, Emr SD. Receptor downregulation and multivesicular-body sorting. Nat Rev Mol Cell Biol. 2002;3:893-905.
23. Dobrowolski R, De Robertis EM. Endocytotic control of growth factor signalling: multivesicular bodies as signalling organelles. Nat Rev Mol Cell Biol. 2011;13:53-60.
24. Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14:1837-1851.